FDA deals Takeda pipeline setback

Share this article:

The FDA recommended that Takeda halt high-dose clinical studies of its TAK-475 cholesterol drug due to possible liver side effects, asking for additional data on the drug.
 
News of the setback sent shares of Takeda tumbling 12%, to $61.59 on the Tokyo Stock Exchange.

Financial firm Mitsubishi UFJ Securities lowered its rating on Takeda from “3” to “2,” predicting that the overseas launch of TAK-475 could be delayed by more than two years.

Takeda had planned to seek approval for the drug this April and hoped TAK-475 could help replace sales of its best-selling diabetes drug, Actos, when that drug's patent expires in 2011. Actos, with global sales of $2.8 billion, accounted for a quarter of Takeda's revenue last year.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.